Clinical Trials Browser

Phase 4 × Breakthrough Pain × Clear all

NCT02869321 2019-05-13

ANTALGIP

Phase 4 Completed

Head and Neck Neoplasms, Breakthrough Pain

NCT00576173 2010-04-28

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

Phase 4 Completed

Cancer Pain, Pain, Breakthrough Pain